Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p476 | Paediatric bone disease | ECTS2016

Childhood fractures in northern Norway: a population-based study, Fit Futures

Christoffersen Tore , Winther Anne , Nilsen Ole Andreas , Ahmed Luai Awad , Furberg Anne-Sofie , Emaus Nina

Background: Fractures are common injuries during childhood. Incidence rates and patterns varies, but population-based data are scarce. The aim of this study was to describe a population based sex, age and maturation specific incidence of fractures at different anatomical sites in a representative sample from regions above the Arctic Circle.Methods: All fractures in the population based convenient cohort Fit Futures, comprising 1038 adolescents mainly bor...

ba0006p004 | (1) | ICCBH2017

Bone mass tracks into teenage years

Ronne Maria , Heideman Malene , Schou Anders , Laursen Jens Ole , Wedderkopp Niels , Husby Steffen , Molgaard Christian

Objectives: Bone mass development in childhood and adolescence is crucial for peak bone mass (PBM) and low PBM may lead to osteoporosis later in life. The stability of bone mineral status through childhood and adolescence is known as tracking. The objective of this study is to determine the degree of tracking according to bone mass from pre-puberty into puberty in healthy Danish children.Methods: 190 healthy Danish children (97 boys) with mean age 9.25 y...

ba0003pp164 | Cell biology: osteoclasts and bone resorption | ECTS2014

Novel highly sensitive ELISA to measure free, bioactive, human soluble RANKL

Suciu Andreea , Breitwieser Andreas

RANKL, the receptor activator of nuclear factor kappa B ligand, is an essential factor for the formation of mature osteoclasts. Together with its receptor RANK and its antagonist Osteoprotegerin (OPG) RANKL is a key regulator in bone metabolism1. RANKL is a membrane-bound protein that can be segregated to a soluble form (sRANKL), whereas only the latter has been reported to be bioactive2. Due to its low circulating levels and the nature of the analyte bin...

ba0002p173 | (1) | ICCBH2013

Vitamin D prescription: a review of British National Formulary for children recommendations, and a proposal

Kouklinos Andreas , Lim Julian , Jacobs Benjamin

Aims: To review changes in the advice regarding vitamin D deficiency in the UK and compare these with other national guidance.Methods: All Vitamin D guidance in the Royal College of Paediatrics and Child Health 2003 guide (Medicines for Children) and in the eight editions since the British National Formulary for Children (BNFc) was first published in 2005 was reviewed.Results: Dosage and indications of prevalence are shown in the T...

ba0003pp304 | Osteoporosis: treatment | ECTS2014

Activin decoy receptor (IIA) ameliorates immobilisation induced loss of bone and muscle mass in mice

Lodberg Andreas , Thomsen Jesper Skovhus , Bruel Annemarie

Activin is a known physiologic regulator of bone metabolism. Ovariectomy-induced osteopenia has been shown to be attenuated by injection of the activin type IIA decoy receptor (ActRIIA-Fc). However, immobilization-induced osteopenia is driven by different pathways than ovariectomy-induced osteopenia, and the role of activin in immobilization-induced osteopenia has not yet been elucidated.The purpose of the study was to investigate the possible attenuatio...

ba0001pp364 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Osteoporosis an independent predictor of mortality in hip fracture patients

Diamantopoulos Andreas P , Hoff Mari , Hochberg Marc , Haugeberg Glenn

Introduction: Mortality after hip fracture is increased. However, only a few studies have explored for predictors beyond gender and age. Thus our aim was to study risk factors associated with increased mortality in hip fracture patients.Methods: Hip fracture patients (>50 years) admitted to a county hospital in 2004–2005 were consecutively invited for assessment at the hospital osteoporosis centre. A broad spectre of data was collected. Standard...

ba0002p171 | (1) | ICCBH2013

Vitamin D levels and signs of metabolic bone disease in adolescents with idiopathic scoliosis

Adodra Annika , Kouklinos Andreas , Julies Priscilla , Shaw Mathew , Jacobs Benjamin

Objective: Biochemical assessment of teenage patients with adolescent idiopathic scoliosis (AIS).Methods: Blood sampling from 120 patients with AIS aged 12–17 years. The patients all had significant scoliosis and blood samples were taken a few days or weeks before they underwent scoliosis surgery. Serum 25-hydroxy-vitamin D (25-OHD), calcium, phosphate, alkaline phosphatase and parathyroid hormone (PTH) were measured. Patients with a 25-OHD level be...

ba0003pp37 | Bone biomechanics and quality | ECTS2014

Bone matrix mineralization after sclerostin antibody treatment in a mouse model of osteogenesis imperfecta

Roschger Andreas , Roschger Paul , Kneissel Michaela , Rauch Frank

Children with osteogenesis imperfecta (OI) still suffer from frequent fractures, despite bisphosphonate treatment. Thus new therapeutic approaches are needed. Sclerostin is a protein that is thought to inhibit bone formation. Treatment with sclerostin antibodies (SclAB) increases bone mass in animal models and in clinical trials and may be a rational therapy for OI as well.Transgenic (TgOI) Col1a1Jrt/+ mice were gene...

ba0003pp309 | Osteoporosis: treatment | ECTS2014

Treatment of severe vertebral osteoporosis with teriparatide or 1--84-PTH: results from a Danish Database Initiative

Hyldstrup Lars , Langdahl Bente L , Eiken Pia , Hermann Pernille , Schwarz Peter , Moeller Marianne Kleis , Bennedbaek Finn , Madsen Ole Rintek , Abrahamsen Bo , Stilgren Lis , Smitz Anita , Pelch Randi , Brockstedt Helle , Jarlov Anne , Morch Marianne , Sorensen Henrik Ancher , Mortensen Lene , Andreasen Per Nygaard , Hoeck Hans Christian , Jensen Jens-Erik Beck

A Danish database initiative was established in 2003 with the purpose of evaluating patients treated with teriparatide. After the introduction in 2006 of 1–84-PTH, these patients were also included. A total of 1494 patients from 19 centers were reported to the database, until closure in 2011. The reported patients correspond to a third of all patients in Denmark receiving anabolic treatment during this time period. With regard to age and sex the reported patients do not d...